-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMX-818 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMX-818 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMX-818 in Solid Tumor Drug Details: AMX-818 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMX-500 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMX-500 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AMX-500 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: AMX-500...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMX-818 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMX-818 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AMX-818 in Solid Tumor Drug Details: AMX-818 is under development for the treatment...
-
Company Profile
Genentech USA Inc – Company Profile
Genentech USA Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology, and infectious disease, among others. The company’s pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the...
Add to Basket -
Product Insights
Colorectal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colorectal Cancer Pipeline Products Market Report Overview Colorectal cancer starts in the colon or the rectum. It begins as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools, and weight loss with no known reasons. Risk factors for colorectal cancer include smoking, heavy alcohol use, inflammatory bowel disease (IBD), and family history. Treatment...
-
Track & Monitor
Biosimilars in Pharmaceuticals: Hormone-based therapies for metabolic disorders
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Hormone-based therapies for metabolic disorders segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Peptide-based inhibitors for cancer treatment
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Peptide-based inhibitors for cancer treatment segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AMX-818
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AMX-818 Drug Details AMX-818 is under development for the treatment of HER2 low expressing...